Fundraising FoxDimension Therapeutics
acquired by Ultragenyx PharmaceuticalCambridge, US · Founded 2013 · Delaware corporation · 3 known investors
Find your way into Dimension Therapeutics
Sign up to see every warm intro you have to Dimension Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Dimension Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Ultragenyx Pharmaceutical October 2017 · $152.3M ($6.00 per share, approximately $152.3 million in cash) · source ↗
Dimension Therapeutics was a Cambridge, Massachusetts biopharmaceutical company developing AAV-based gene therapies for rare liver-associated metabolic diseases like hemophilia, OTC deficiency, and glycogen storage disease.
Founders & leadership
Board
Investors · 3
How we know: F-Prime Capital's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$89.5M disclosed across 2 rounds · 2013–2015
▶$65MraisedApr 2015 · 12 investors · BiotechnologyRule 506(b)
- Rishi GuptaDirector
- Donald J. Hayden, Jr.Director
- Benjamin AuspitzDirector
- Jay K. HachigianExecutive Officer
- Annalisa JenkinsExecutive Officer, Director
- Offering amount
- $65M
- Amount sold
- $65M
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$24.5MraisedFeb 2015 · 2 investors · Other TechnologyRule 506(b)
- Donald J. HaydenDirector
- Benjamin AuspitzDirector
- Annalisa JenkinsExecutive Officer, Director
- Allan FoxDirector
- Offering amount
- $24.5M
- Amount sold
- $24.5M
- First sale
- Oct 2013
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Dimension Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Dimension Therapeutics do?
- Dimension Therapeutics was a Cambridge, Massachusetts biopharmaceutical company developing AAV-based gene therapies for rare liver-associated metabolic diseases like hemophilia, OTC deficiency, and glycogen storage disease.
- Who are Dimension Therapeutics's investors?
- Dimension Therapeutics's investors include F-Prime Capital, New Leaf Venture Partners, OrbiMed.
- How much funding has Dimension Therapeutics raised?
- Dimension Therapeutics has disclosed $89.5M raised across 2 rounds.
- Who acquired Dimension Therapeutics?
- Dimension Therapeutics was acquired by Ultragenyx Pharmaceutical.
- Where is Dimension Therapeutics headquartered?
- Dimension Therapeutics is headquartered in Cambridge, US.